Sinha Vikas 4

4 · Verona Pharma plc · Filed May 22, 2025

Form 4

Period: 2025-05-20

Director

Transactions

Exercise/Conversion
Ordinary Shares
2025-05-20$0.50/sh+160,000$80,608→ 234,440 total
Sale
Ordinary Shares
2025-05-20$9.39/sh−160,000$1,502,928→ 74,440 total
Exercise/Conversion
Share Options (Right to Buy)
2025-05-20−160,000→ 384 total
Exercise: $0.50Exp: 2032-04-27→ Ordinary Shares (160,000 underlying)

Footnotes (6)

[F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
[F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2024.
[F3]The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $9.375 to $9.4263, inclusive (or $75.00 to $75.41 per ADS, inclusive). The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
[F4]Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.
[F5]The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
[F6]The option is fully vested.

Documents

1 file